Effectiveness of a Digital Telemonitoring Platform for the Care of Elderly Patients with Cancer

2021 Year in Review: Non–Small-Cell Lung Cancer —December 29, 2021

Categories:

Lung Cancer

More than half of all new malignancies are detected in elderly patients aged >70 years. The COVID-19 pandemic was especially difficult for elderly patients, as they are the most vulnerable to cancer and COVID-19 infection. During this time, telemedicine has certainly advanced, but its place in elderly patient care has not been fully determined. The ConnectPatientToDoctor research was designed to assess a connected telemonitoring platform for elderly patient cancer care.1

This prospective study was undertaken on patients with cancer aged >70 years at the Bégin Military Teaching Hospital, Saint-Mandé, France. Patients were given the option of filling out a Common Terminology Criteria for Adverse Events version 5.0–based symptomatology questionnaire that was tailored to their pathology and treatment. Based on the reported adverse events, an algorithm analyzed the patients’ health status and categorized them into 4 states: Correct (A); Compromised (B); Monitoring State (C); Critical State (D). In cases A and B, the patient was given therapeutic counsel to help manage each of the adverse occurrences that had been documented. The patient was encouraged to call the hospital in the other states (C and D). The main end point was to determine if the elderly patient was compliant with the linked platform. The satisfaction of the patients was a secondary end point.1

Between July 1, 2020, and March 31, 2021, 54 patients were enrolled. The average age was 78 years. Prostate cancer was the most common cancer, with 69% having reached a metastatic stage. Most (70%) patients were compliant and reacted at the expected intervals (every 1 or 2 weeks). In total, 1412 surveys were completed, yielding 529 B-state responses and 145 C- or D-state responses. Outpatient care was used to manage more than 60% of the warnings. Patients were happy in 72% of cases.1

The continued lack of healthcare resources, as well as the rising cancer incidence, underline the need for new ways to ensure that all patients receive the best possible treatment, care, and follow-up. Digitalized healthcare, which encompasses a number of ideas (digital health, telemedicine, telemonitoring, and digital therapeutics), is a viable way to address these demands.2 To prevent further segregating patients with poor and high digital health literacy, it is important for healthcare workers to be aware of the challenges to engagement that the elderly patients face. On a societal level, solutions to improve this issue include increasing Internet accessibility, training digital skills, and boosting social support for elderly patients.3 Elderly patients clearly benefited from the use of this platform in this study. Patients reported feeling less isolated and benefiting from personalized care. The elderly patient care procedure could be streamlined using this type of platform.1

References

  1. Helissey C, Duverger C, Vanquaethem H, et al. Effectiveness of a digital telemonitoring platform for elderly cancer patient (EP) care. Ann Oncol. 2021;32(suppl 5):S1187-S1188.
  2. Bouaoud J, Bertolus C, Zrounba P, Saintigny P. Digitalized healthcare for head and neck cancer patients. J Stomatol Oral Maxillofac Surg. 2021;122:434-440.
  3. Jonker LT, Lahr MMH, Festen S, et al. Perioperative telemonitoring of older adults with cancer: Can we connect them all? J Geriatr Oncol. 2020;11:1244-1249.
Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country